Clinical trialNCT05488340RecruitingPhase 2Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

SponsorLocus BiosciencesEnrollment318Urinary Tract Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Paul Kim
Locus Biosciences
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Research Site 138
Fresno, California, United States
Completed
Research Site 131
Lancaster, California, United States
Recruiting
Research Site 123
Los Angeles, California, United States
Recruiting
Research Site 125
Montebello, California, United States
Completed
Research Site 152
Murrieta, California, United States
Recruiting
Research Site 137
San Diego, California, United States
Recruiting
Research Site 126
Tustin, California, United States
Recruiting
Research Site 102
Doral, Florida, United States
Recruiting
Research Site 151
Hialeah, Florida, United States
Recruiting
Research Site 140
Jensen Beach, Florida, United States
Completed
Research Site 103
Miami, Florida, United States
Recruiting
Research Site 149
Miami, Florida, United States
Recruiting
Research Site 153
Ocala, Florida, United States
Recruiting
Research Site 120
Boston, Massachusetts, United States
Completed
Research Site 154
St Louis, Missouri, United States
Recruiting
Research Site 145
Raleigh, North Carolina, United States
Recruiting
Research Site 118
Winston-Salem, North Carolina, United States
Completed

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LBP-EC01LBP-EC01 0.01x IV DoseLBP-EC01 0.1 x IV doseLBP-EC01 IV Infusion DosePlaceboThymidine monophosphate

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Jul 2022
Primary completion: 30 Jun 2027
Completion: 31 Dec 2027
Last update posted: 14 Sept 2026
Registered enrollment: 318
Registry id: NCT05488340

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.